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As  a result  of thermal  instability,  some  live  attenuated  viral  (LAV)  vaccines  lose  substantial  potency  from
the  time  of  manufacture  to the  point  of  administration.  Developing  regions  lacking  extensive,  reliable
refrigeration  (“cold-chain”)  infrastructure  are  particularly  vulnerable  to vaccine  failure,  which  in  turn
increases  the  burden  of  disease.  Development  of a robust,  infectivity-based  high throughput  screening
process  for identifying  thermostable  vaccine  formulations  offers  signiﬁcant  promise  for  vaccine  develop-
ment  across  a wide  variety  of LAV  products.  Here  we  describe  a system  that  incorporates  thermal  stabilityeasles
hermostability
ormulation
igh-throughput
old-chain
ates Foundation Grand Challenges in
screening  into  formulation  design  using  heat  labile  measles  virus  as a  prototype.  The screening  of >11,000
unique  formulations  resulted  in  the identiﬁcation  of  liquid  formulations  with  marked  improvement  over
those  used  in  commercial  monovalent  measles  vaccines,  with  <1.0  log  loss  of  activity  after  incubation  for
8  h  at  40 ◦C. The  approach  was  shown  to  be transferable  to a second  unrelated  virus,  and  therefore  offers
signiﬁcant  promise  towards  the optimization  of  formulation  for LAV  vaccine  products.
© 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.
lobal Health
. IntroductionIt is estimated that 50% of lyophilized vaccines are dis-
arded annually [1], and temperature instability is an appreciable
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Open access under CC BY-NC-ND license.contributing factor in this wastage. The majority of vaccines, par-
ticularly live attenuated viral (LAV) vaccines against measles and
polio [2,3], require careful temperature regulation from the point of
manufacture through administration to preserve their stability and
therefore efﬁcacy [4,5], i.e. the cold chain. Although this challenge
is largely solved in developed markets, in much of the developing
world, where ambient temperatures can exceed 40 ◦C, the cold-
chain infrastructure is incomplete or unreliable. Failures in the cold
chain have contributed to local outbreaks and the resurgence of
disease in the developing world [6–14].
The development of thermostable vaccines would dramatically
improve access to effective vaccines to the global populations most
in need and represents a major step to realizing the full bene-
ﬁt of vaccines in preventing infectious diseases and saving lives
worldwide [15–18]. However, the development of thermally stable
vaccine formations presents signiﬁcant technical challenges and is
of little commercial interest to major pharmaceutical companies
focused on the developed world. As a result, preparation of “Vac-
cines That Do Not Require Refrigeration” was identiﬁed as one of
the 14 Grand Challenges in Global Health put forth by the Bill &
Melinda Gates Foundation [19].
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Fig. 1. Infectivity-based image analysis. (a) A Vero cell monolayer infected
with  recombinant measles virus expressing enhanced green ﬂuorescent protein
(MVeGFP)  in a single well of a 96-well plate with (+) and without (−) FIP addition
at  1 h post-inoculation. Absence of FIP results in cell–cell fusion (syncytia) prevent-
ing  quantitation of discrete, infected cells. (b) Representative images from a single
2-fold virus dilution series, showing the number of ﬂuorescent objects (individual
MVeGFP-infected  cells, +FIP) counted by a custom image analysis algorithm. (c) The
response of the assay is linear up to ∼1600 object counts (r2 = 0.995), a dynamic range
of ∼2.2 log units. In order to normalize virus counts for each experiment, a single
control  formulation was included on every plate. Through a priori statistical power
analysis, 16 control replicates per 96-well plate and 8 test replicates per experiment
were  considered sufﬁcient to achieve the desired power of 0.9 and speciﬁcity of 0.8
at a standardized effect size of 1.0. In practice, 10 replicates of each formulatione 29 (2011) 5031– 5039
Measles LAV is an ideal candidate for reformulation. Despite
the existence of a safe and effective vaccine, the World Health
Organization reports 25–30 million cases of measles each year
and measles remains a leading cause of vaccine-preventable death
among children under 5 years old. Recent reinvigorated efforts
across a broad spectrum of approaches have helped reduce measles
deaths worldwide from 750,000 in 2000, but there were still an
estimated 197,000 fatalities in 2007 [20]. Interruption of endemic
transmission of measles virus (MV) requires that >95% of the popu-
lation be immune [21], highlighting the need for complete, effective
vaccination coverage in communities.
MV is inherently labile, losing 50% potency after 1 h at 22–25 ◦C
and almost 100% after 1 h at 37 ◦C [22]. Reducing the moisture con-
tent in the vaccine, most commonly through lyophilization [17],
or alternatively through spray drying [23], can lead to dramatic
improvements in the stability of the vaccine during storage and
distribution; however, reconstitution prior to vaccination is still
required. Even successful commercial LAVs such as Attenuvax®
(Merck) lose 1 log of potency after 8 h at 37 ◦C in the reconstituted
(liquid) form (internal data). Although single dose vials are used in
developed countries, multi-dose vials are ubiquitous in the devel-
oping world due to cost considerations. In practice, a vial may  be
reconstituted and kept so throughout the course of a full clinic
day, without adequate cooling and without adherence to the WHO
guidelines around diluent temperature, storage temperature and
time, and discard [24]. Thus, improvement in the stability of liq-
uid (reconstituted) measles vaccine at ambient temperatures could
deliver signiﬁcant value in the developing world.
Herein we describe the development of a high throughput (HT)
screening platform capable of simultaneously evaluating the ther-
mostability performance for hundreds of MV formulations. The HT
approach is ideal for complex vaccine formulations because of the
intensive and time-consuming nature of traditional formulation
development and the enormity of the possible formulation space.
Using this HT process, we  identiﬁed multiple formulations capa-
ble of maintaining the potency of the vaccine in the liquid state at
40 ◦C for at least 8 h. These formulations may  offer increased ther-
mal stability for a monovalent measles vaccine when compared to
currently marketed products, and in some cases also offer a cost
beneﬁt and eliminate the need for animal-derived components.
2.  Materials and methods
2.1.  Commercial vaccines
The  measles vaccine Attenuvax® (Merck) contains phosphate
buffer, sodium chloride, stabilizers (sorbitol, sucrose, hydrolyzed
gelatin, and human albumin), and residual culture medium [25].
The measles vaccine M-VACTM (Serum Institute of India) includes
tricine, amino acids (alanine, arginine, histidine), and stabilizers
(lactalbumin hydrolysate, hydrolyzed gelatin) [26].
2.2.  Measles virus growth and harvest
Measles virus encoding enhanced green ﬂuorescent protein [27]
(MVeGFP) was  grown by infecting a 50% conﬂuent monolayer of
Vero cells (CCL-81, ATCC) in 100 mm cell culture plates (Corning)
at a 0.015 multiplicity of infection in OptiMEM (GIBCO). After 1-h
incubation at 37 ◦C/5% CO2, OptiMEM containing 2% fetal bovine
serum (FBS, GIBCO) was  added to the inoculated cells. Cells were
further incubated at 37 ◦C/5% CO2 until 90–100% of cells exhib-
ited cytopathic effect. To harvest virus, infected cells were scraped
from plates, and excess growth medium was removed following
low speed centrifugation (300 × g). Cell pellets were resuspended
in 2 ml  of OptiMEM, freeze-thawed, and centrifuged. Resulting
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upernatant containing virus was titered using the assay described
n Section 2.3, aliquoted, and stored at −80 ◦C. To expand stocks
f Moraten and Edmonston-Zagreb viruses from Attenuvax® and
-VACTM vaccines (respectively), lyophilized vaccines were recon-
tituted, serially diluted into serum-free DMEM (GIBCO), and added
o Vero (Moraten) or MRC-5 (Edmonston-Zagreb) cells (CCL-171,
TCC) and then processed as described for MVeGFP.
.3. Fluorescent infectivity assay
Vero cells were seeded at 2 × 104 cells/well in DMEM containing
% FBS on 96-well ViewPlates (Perkin Elmer). Following a 1 h room
emperature incubation [28], cell plates were incubated overnight
t 37 ◦C/5% CO2. Virus was diluted 1:9 into formulation and ther-
ally challenged. After further diluting 1:3 into OptiMEM, samples
ere added to cells (25 L) and centrifuged at low speed (311 × g)
or 10 min. Assay plates were incubated at 37 ◦C/5% CO2 for 80 min
o allow viral adsorption to cells. Fusion inhibitory protein (FIP, Z-
-Phe-Phe-Gly-OH, Bachem), dissolved in DMSO and diluted to a
nal concentration of 155 M in OptiMEM containing 2% FBS/1%
enicillin–streptomycin (GIBCO), was then added to wells (75 L)
o prevent syncytia formation and secondary infection. After 30 h
t 37 ◦C/5% CO2, cells were ﬁxed with 4% paraformaldehyde (EMS).
mages were captured with a Cellomics VTi Arrayscan using a FITC
lter and 2.5× objective lens (Fig. 1). Infectious units (‘IU’) denote
he titer of virus determined from the ﬂuorescence-based assay
s opposed to plaque-forming unit (pfu) titer measured by plaque
ssay.
.4. High throughput (HT) experimentation
The complete HT formulation procedure will be described else-
here (Development of an integrated high throughput system
or identifying formulations of live virus vaccines with greater
hermostability: application to the monovalent measles vaccine;
anuscript in preparation). In brief, in-house Design of Experiment
oftware created screening protocols. After 1.11× unary stock for-
ulation creation (to account for 1:9 dilution with measles stock),
 high-throughput combinatorial liquid dispenser created com-
lex formulations in 96-well deepwell plates (Matrix). A Hamilton
tarlet transferred formulations to 96-well assay plates (Corning).
irus was diluted to 8 × 106 IU ml−1 in OptiMEM and added into
he BioCube (Protedyne). The remainder of the process is described
n Fig. 2 and the ﬂuorescent infectivity assay. For each formulation
n HT experiments, n = 4–10.
.5.  Automated image analysis
Automated  image analysis was performed on each well of
6-well assay plates using a custom image analysis algorithm
eveloped using the Matlab image processing toolbox environment
version R2006b, MathWorks).
.6.  Excipients in validation experiments
l-Asparagine anhydrous, sodium d-gluconate, glycine, sodium
ulfate anhydrous, l-serine, d-(+)-trehalose dihydrate, l-valine, and
ricine were obtained from Sigma–Aldrich. Sodium citrate dihy-
rate and sucrose were obtained from JT Baker. GELITA SOL-KKA
porcine) gelatin was obtained from Gelita USA.
.7. MVeGFP validation assayThe validation assay was conducted in a similar manner to
he method described above with the following modiﬁcations. To
nsure that Moraten virus from Attenuvax® did not affect MVeGFP 29 (2011) 5031– 5039 5033
infection,  Attenuvax® was  exposed to visible light (at room tem-
perature) in order to photoinactivate [29] the vaccine-strain virus.
MVeGFP was  then diluted (∼1:200) into Attenuvax® while the
remaining formulations were prepared as previously described. At
each timepoint, n = 24/formulation.
2.8.  Moraten measles virus ﬂuorescence assay
The Moraten assay was  performed as described for the MVeGFP
validation assay with the following modiﬁcations. Following ther-
mal  challenge, reconstituted Attenuvax® was diluted 1:5 into
OptiMEM. For non-Attenuvax® formulations, Moraten virus was
diluted to 8 ×105 IU ml−1 in OptiMEM prior to addition to formu-
lation. After ﬁxation, cells were permeabilized with 1% Triton-X for
5 min  at room temperature and incubated with 1:500 antibody to
measles nucleoprotein (MAB8906F, Millipore) for 30 min  at 37 ◦C
prior to imaging. At each timepoint, n = 12/formulation.
2.9. Plaque assays
Serial  dilutions of formulated virus was added to 50% conﬂuent
Vero cells in 6-well plates (Corning). After 4 h at 37 ◦C/5% CO2, cells
were overlaid with DMEM containing 1% methylcellulose/2%FBS
and  further incubated for 5 days. Cells were ﬁxed with 1% crys-
tal violet in methanol and plaques manually counted under a light
microscope. Titer was calculated by multiplying average plaque
count (from duplicate wells) by dilution factor. For thermal chal-
lenge, vaccines were reconstituted per manufacturers’ instructions.
At each timepoint, n = 2/formulation.
2.10.  Adenovirus transferability assay
Adenovirus (Ad-CMV-eGFP; Vector Biolabs) assays were con-
ducted using similar methods described for MVeGFP except there
was neither a centrifugation step nor FIP added post-inoculation.
Cells were ﬁxed and analyzed after 72 h of infection. At each time-
point, n = 24.
3. Results
3.1. Bioassay development and optimization
Live measles vaccine potency directly correlates with infectivity
[16]. WHO  requirements describe two  alternative ways of deter-
mining the potency of live measles vaccine: measurement of plaque
forming units (PFU) or tissue culture infective doses (TCID50). Both
assays are time intensive, highly variable, and limited in throughput
as they require expert visual analysis. Thus, a novel, quantitative
cell-based in vitro measles infectivity assay (Fig. 1) for quanti-
fying the infectivity of MV  in standard 96-well microtiter plates
was developed. The ﬂuorescence-based assay uses a recombinant
Edmonston-derived laboratory-adapted MV expressing enhanced
green ﬂuorescent protein (MVeGFP) [27] and is quantitated using
automated image analysis. The assay has a wide dynamic range
(≥2.0 orders of magnitude), low variability (Relative Standard Devi-
ations, RSDs ≤30%, as measured through the thousands of control
formulations across the screening campaign), and short duration
(<4 days).
Two  additional measures not typically used during measles
infection were implemented to optimize this assay for the HT
screening process. First, fusion inhibitory protein (FIP) was used
to prevent cell-to-cell spread and therefore secondary infections,
and thereby increase the dynamic range of the assay. In a typical
MV infection, neighboring cells fuse to form multinucleated syncy-
tia, which markedly vary in size, shape, brightness and sharpness.
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Fig. 2. High-throughput (HT) assay for the determination of formulation-dependent thermal inactivation of MV.  Formulations were created from individual excipient stock
solutions  dispensed to 96-well microtiter plates according to the experimental design using automated liquid handling instruments. All further operations were conducted
on  a custom-built, fully integrated robotic BioCube system (Protedyne, Inc; Windsor, CT). Within the automated system (a), the experimental process (b) begins when the
(1)  MVeGFP is combined with (2) unique formulations. (3) Formulated virus is thermally challenged at an elevated temperature, diluted 1:3 into OptiMEM, and added to
(4)  Vero cell monolayers in (5) 96-well plates. (6) Plates are centrifuged and brieﬂy incubated to facilitate primary infection and (7) fusion inhibitory protein (FIP) is added
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ao  prevent secondary infection. (8) After 30 h of incubation at 37 ◦C, (9) cells are ﬁ
he BioCube and imaged on a Cellomics Arrayscan. The resulting images are analyz
rotection conferred by a formulation to the virus, the higher the cell infectivity, an
hysical overlaps between syncytia create an upper limit on
ynamic range, and their non-uniform appearance makes accurate
uantiﬁcation challenging, especially when using automated image
nalysis. FIP prevents syncytia formation through an unknown
olecular mechanism [30]. When FIP is added shortly after the ini-
ial infection, ﬂuorescent infectious centers remain discrete, single
bjects of uniform size and shape (Fig. 1a), each representing a sin-
le cell infected by MVeGFP. Second, the relatively low titer of MV
n typical cell culture (∼106 plaque-forming units) plus the addi-
ional reduction of virus concentration as a result of its dilution
nto formulation places limits on the upper bound of detection. In
rder to address these challenges, we introduced a “spinoculation”
tep. Centrifugation of inoculated cell monolayers at low speed has
een shown to enhance the detection of viable virus (e.g. for HIV
31]), presumably by bringing infectious particles into close con-
act with the cells, thereby facilitating infection. Addition of FIP
o the viral inoculum prior to centrifugation completely eliminated
nfection, suggesting that the molecular mechanism of viral entry is
ot affected (results not shown). Spinoculation, however, causes an
pparent increase in viral titer of approximately 0.5 log10 increas-
ng the upper end of the range (Fig. 1b). This apparent increase in
iter reduces consumption of virus during HT screening and allows
or greater dilution of virus stock into formulation.
FIP and spinoculation increase the dynamic range of the assay
pproximately 2.5-fold from 1.8 logs (∼5 to ∼300 object counts,
ata not shown) to ∼2.2 logs (∼10 to ∼1500 object counts) and
enerate reproducible, robust data (RSDs of 5–15%) (Fig. 1c), thus
ffering signiﬁcant advantages over traditional plaque or TCID50
ssays.
.2. Assay automation
In  order to achieve the desired throughput (>104 formulations),
e developed an integrated system (Fig. 2a), combining software
including design of experiment, sample tracking, data visualiza-
ion, and analysis), hardware (liquid dispensing, plate handling, and
uorescence imaging), and experimental workﬂow (Fig. 2b) (Devel-
pment of an integrated high throughput system for identifying
ormulations of live virus vaccines with greater thermostability:
pplication to the monovalent measles vaccine; manuscript inith paraformaldehyde and stored in PBS. (10) Plates are manually removed from
ng a custom algorithm (Supplementary Algorithm online). The greater the thermal
s the higher the ﬂuorescent “object count.”.
preparation).  A combination of in-house designed, custom modi-
ﬁed, and off-the-shelf hardware and software were used.
The  impact of intra- and inter-plate systematic variability typ-
ical of cell-based assays in microtiter plate formats [32] was
reduced through careful experimental design choices and data
normalization using on-plate controls. The solutions implemented
to overcome these challenges will be discussed in greater detail
separately (Maximizing the value of cell-based high throughput
screening data through experimental design and data normaliza-
tion; manuscript in preparation).
In HT small molecule screening it is common practice to evaluate
the performance of the assay based on the negative and posi-
tive controls (Z′) [33] and the proportion of hits found (i.e. hit
rate). In thermal stability screening of virus formulations, neither a
true negative control (no infectivity) nor a true positive control is
informative. In theory, it is possible to benchmark formulation per-
formance against either a commercial vaccine or the pre-thermal
challenge viral titer for each assay. However, this proved impossi-
ble in practice due to the limited availability of monovalent vaccine
and the impracticality of processing non-thermally challenged con-
trol plates simultaneously with thermally challenged samples. In
practice, the primary goal of identifying formulations capable of
thermally stabilizing the virus was  readily achieved through simple
rank ordering of formulation performance, followed by validation
of ‘high performing’ hits using manual assays such as plaque assays.
3.3. Formulation screening strategy
A formalized screening strategy to guide experimental design
was applied. A list of >200 excipients including buffers, stabi-
lizers, solubilizers, preservatives, and toniciﬁers compiled from
marketed parenteral formulations, the FDA ‘Generally Regarded
As Safe’ (GRAS) list, and the literature was  narrowed based on
considerations of safety, cost, manufacturing, and ethical issues.
Ultimately, 98 unique excipients were screened (Supplementary
Table Online).The  fully combinatorial formulation space represented by 98
excipients is many orders of magnitude larger (1 × 109 unique for-
mulations with just 6 excipients each) than is tractable, even for
HT screening (∼104). Therefore, a ‘linear’ strategy was devised in
L.D. Schlehuber et al. / Vaccine 29 (2011) 5031– 5039 5035
Table 1
High  throughput screening stages.
Stage Excipient classes Formulation
order
Variables Control formulation Unique formulations
1 Buffers 1 Excipient (17)
Concentration (5)
pH  (7)
Mimic  of Attenuvax® 218
II Buffers,  stabilizers 2 Excipient (70)
Concentration (3)
Sodium  citrate pH 7.4, 50 mM 3134
III Buffers,  stabilizers 4 Excipient (50) Sodium citrate pH 6.0, 50 mM 2740
IV Buffers,  stabilizers,
antioxidants, chelating agents
5–8 Excipient (18) 2.9% (w/v) porcine gelatin in
sodium citrate pH 6.0, 50 mM
3200
V Buffers,  stabilizers,
antioxidants, chelating agents
4 Excipient (22)
Concentration (3)
2.9%  (w/v) porcine gelatin,
asparagine 50 mM,  and
trehalose 100 mM in sodium
citrate pH 6.0, 50 mM
1280
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Total  
hich formulations of increasing complexity were evaluated in ﬁve
Stages,’ each comprised of multiple individual screens (Table 1).
he best performing formulations (highest object counts) were
dentiﬁed from each screen and taken forward as the basis of the
esign of the more complex formulation space to be evaluated in
he next stage.
A  linear strategy inherently risks missing any dramatic synergis-
ic effects between excipients that are never tested in combination
having been eliminated from consideration during earlier steps)
nd the true maxima in concentration space (which is only explored
oarsely). To reduce these risks, 4 additional screens aimed to cover
oth a broader sampling of the overall formulation space (‘shotgun’
creens) or to ﬁnely explore concentration effects of promis-
ng formulations (‘targeted’ screens) were interspersed in the
rocess.
.4. HT screening results
A  total of 11,823 unique formulations (as deﬁned by combina-
ion of excipients, excipient concentrations, and pH) were screened
n 35 HT screens comprising 5 stages of linear screening and addi-
ional non-linear screens (Table 1, full and summarized datasets in
upplementary Data Online). Intra-assay variability was typically
n the range of 10–25% RSDs normalized across control formula-
ions, and all assays reported had RSDs below 30%. The highest
erforming formulations (based on rank ordered normalized object
ounts) were selected at each stage as the basis of the design of
he subsequent stage. Pairwise comparisons of formulation perfor-
ance quoted are signiﬁcant at the p < 0.05 level by standard t-test,
ith 4–10 replicates per formulation. A small number of datapoints
ttributed automation error were removed from the calculations.
n general, as the complexity of the formulations increased with
rogression through the stages, the performance of the top formu-
ations from each stage increased. Increases in performance were
ncremental or additive at best, and no truly synergistic effects
AB  A + B) were observed.
Stage I was designed to broadly assess the effect of buffers on
iral stability (29 variables, 218 unique formulations). Citrate pH
.4, citrate pH 6.0, potassium phosphate pH 7.4, and histidine pH
.4 were identiﬁed as the highest performing buffers. In Stage II,
hey were combined with stabilizers (73 variables, 3134 unique
ormulations). Formulations containing gelatin, valine, citrate, and
rehalose were typically high performing, and citrate pH 6.0 was
enerally the best performing buffer background. In Stage III (50
ariables, 2740 unique formulations), higher order combinations62)
ion (3)
As  per screening stage 1251
11,823
of  the same excipients used in Stage II yielded increased perfor-
mance.
A non-linear screen examined the effects of varying the concen-
trations in two  high-performing quaternary formulations identiﬁed
in Stage III (Fig. 3a). In both cases, the highest performing concen-
tration combinations had approximately 30% higher counts than
the single combination tested in the Stage III screen, suggesting that
simultaneous co-optimization of concentrations can signiﬁcantly,
but probably not radically, improve formulation performance. In a
second non-linear screen, additional excipients from several new
classes (including antioxidants, chelating agents, and surfactants)
were tested (Fig. 3b). High performers included sodium gluconate
and xylitol, which were then included in the design of Phase IV. Both
positive (e.g. sodium gluconate) and negative (Tween 20 and Tween
80) concentration effects were observed. At higher concentrations,
Tween likely shifts from behaving like a stabilizer to becoming a
detergent, causing disruption of the virion lipid envelope. Likewise,
non-polar amino acids were better performers than other classes
of amino acids, but the reasons for this are unclear.
In Stage IV (18 variables, 3200 unique formulations), higher
order formulations (5–8 excipients) including promising
buffer/stabilizer combinations were combined with antioxi-
dants and chelating agents. The same excipients continued to
perform well, including citrate pH 6.0, gelatin, trehalose, and
valine. Finally, in Stage V (25 variables, 1280 unique formulations),
a limited concentration optimization of 22 high performing for-
mulations showed that for most excipients stability decreased
as concentrations increased. Interestingly, ionic components
including, MgSO4 and MgCl2 [34], have been shown to affect the
stability of the MV.  Both xylitol and sodium gluconate have been
shown to bind to Ca2+ [35], suggesting one potential mechanism
for the stabilization effect.
Fig.  3c graphically depicts the linear screening strategy by focus-
ing on the progression of formulations tested through all ﬁve stages
that led to a single high-performing ﬁnal candidate formulation,
starting with citrate 50 mM (pH 7.4) in Stage I and building incre-
mentally to a partially concentration optimized formulation of
citrate 50 mM (pH 6.0), gelatin, trehalose, sucrose, asparagine, and
glycine (Formulation C in Table 2) in Stage V.
3.5. Validation and transferabilityIn  order to conﬁrm “hits” identiﬁed during HT screening, a suite
of validation assays were applied following completion of each
screening stage (the ﬁnal validated formulations are described in
Table 2). In the HT assay, the viral inoculum added to cells contains
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Fig. 3. Representative HT screening results. (a) Heat maps showing performance range (top) during excipient concentration optimization of 2 quaternary formulations:
sodium citrate pH 6.0 (25, 50, 100 mM),  trehalose (25, 50, 100 mM),  serine (25, 50, 100 mM),  gelatin (2, 4, 8%, w/v) (middle); sodium sulfate pH 7.4 (25, 50, 100 mM),
potassium phosphate pH 7.4 (10, 25, 50 mM),  gelatin (2, 4, 8%, w/v), asparagine (10, 25, 50 mM)  (bottom). (b) Concentration-dependent effects on thermal stability. Against a
background of citrate pH 6.0 (50 mM)  and gelatin (4%, w/v), 16 excipients were screened at three concentrations (w/v). For each excipient, concentration range is shown with
respect  to the x-axis (lowest concentration on the left, highest concentration on the right). Excipients were tested at 0.1%, 0.2%, and 0.4%, w/v, with the following exceptions:
captisol (2, 4, 8%, w/v); disodium oxalate, propyl gallate, TPGS (0.05, 0.10, 0.20%, w/v); gluconolactone, sodium gluconate (0.5, 1.0, 2.0%, w/v); Tween 20, Tween 80 (0.01, 0.15,
0.02%,  v/v); xylitol (1, 2, 4%, v/v). (c) Thermal stability performance of 100 related formulations (0.85% of the total) illustrating the formulation design progression through
the ﬁve stages of HT screening (numerical range of performance varies by stage). In Stage I, citrate was  among the best performing unary formulations and thus was included
in  Stage II. In binary combination with certain excipients, including gelatin, citrate continued to perform well and was  continued in Stage III, etc. The majority of formulations
screened in Stage IV resulted in <1.0 log loss of virus after 35 ◦C thermal challenge for 16 h.
Table 2
Validated formulations following Stage IV screening.
Formulation Stage Order Formulation recipe
A II 2 Sodium citrate 50 mM pH 6.0, porcine gelatin 4%
B III 4 Sodium citrate 50 mM pH 7.4, porcine gelatin 2.9%, trehalose 100 mM,  valine 50 mM
pH 7.4
C  IV 6 Sodium citrate 50 mM pH 6.0, porcine gelatin 2.9%, trehalose 100 mM,  sucrose
100  mM,  asparagine 50 mM pH 7.4, glycine 100 mM pH 7.4
D  IV 6 Sodium citrate 50 mM pH 6.0, trehalose 100 mM,  asparagine 50 mM pH 7.4, glycine
100 mM pH 7.4, serine 100 mM pH 7.4, sodium gluconate 100 mM
E IV 7 Sodium citrate 50 mM pH 6.0, porcine gelatin 2.9%, sorbitol 100 mM,  asparagine 50 mM
pH 7.4, praline 100 mM pH 7.4, serine 100 mM pH 7.4, sodium gluconate 100 mM
F IV  7 Potassium phosphate (dibasic) 10 mM pH 7.4, porcine gelatin 2.9%, sodium sulfate
100  mM,  sucrose 100 mM pH 7.4, glycine 100 mM pH 7.4, valine 50 mM pH 7.4, sodium
gluconate 100 mM
G IV 8 Potassium phosphate (dibasic) 10 mM pH 7.4, porcine gelatin 2.9%, trehalose 100 mM,
sodium sulfate 100 mM,  asparagine 50 mM pH 7.4, glycine 100 mM pH 7.4, proline
100 mM pH 7.4, sodium sulﬁte 100 mM
H IV 8 Tricine 50 mM pH 7.4, porcine gelatin 2.9%, trehalose 100 mM,  sodium gluconate
100  mM,  glycine 100 mM pH 7.4, serine 100 mM pH 7.4, sucrose 100 mM,  sodium
sulfate 100 mM
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Fig. 4. Validation and transferability of the HT process. (a) Accelerated degradation of MVeGFP for up to 8 h at 40 ◦C in marketed monovalent measles vaccine (Attenuvax® , M-
VacTM) or custom formulations (described in Table 2). Experiment and analysis conducted in a similar manner to HT screening. (b) Plaque assay showing MVeGFP degradation
after 4 h at 40 ◦C in a subset of formulations. (c) Accelerated degradation of Moraten MV for 8 h at 40 ◦C. Experiment conducted as described in (a) except that following
ﬁxation, cells were permeabilized and incubated with measles-speciﬁc, FITC-conjugated antibody. (d) Plaque assay showing Edmonston-Zagreb MV degradation after 4 h
at  40 ◦C. (e) Transferability of screening methods to non-measles virus shown with adenovirus expressing eGFP (Ad-eGFP). Ad-eGFP was added to cell monolayers using a
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d-eGFP  was formulated in basic cell medium, OptiMEM, and thermally challenged
een,  but on different time-scales than for MVeGFP, indicating a difference in intrin
esidual, diluted formulation from thermal challenge which could
ender cells more permissive to infection, and therefore cause an
rtiﬁcial increase in object counts independent from thermal sta-
ilization of virus. All of the high-performing formulations were
onﬁrmed to be not acting through this trivial mechanism (data
ot shown). In accelerated degradation studies over 8 h at 40 ◦C,
ormulations based on citrate and tricine demonstrated superior
tabilizing effects (Fig. 4a) relative to those in a potassium phos-
hate background (data not shown). It is possible that sodium
itrate has a slight deaggregating effect on virus (thereby giving
ise to an apparent increase in viral titer) as opposed to a strictly
rotective effect, as suggested from studies with rotavirus vac-
ine [36]. It is also notable that tricine is the buffer background
f M-VACTM vaccine [26]. After 8 h at 40 ◦C, MVeGFP formulated in
ormulations C and H suffered <1.0 log loss while the commercial
easles vaccines, Attenuvax® and M-VACTM, decreased by 1.4 logs
1.35–1.53) and 1.9 logs (1.67–2.19), respectively. Assessment of
he formulations by the traditional plaque assay closely corre-
ated with the results of the MVeGFP accelerated degradation assayd for MVeGFP quantitation) were in close agreement with the expected counts. (f)
4, 48, or 72 h at 25 ◦C or 37 ◦C. Time- and temperature-dependent inactivation was
rmal stability of the viruses.
(Fig.  4b). Overall, the rank order of formulation stability is identi-
cal for both methods, supporting the validity of the HT screening
strategy.
MVeGFP was used as a surrogate for the HT screens because
ﬂuorescence is an easily quantiﬁable endpoint. The most promis-
ing formulations were validated using the same non-recombinant
measles strains used in commercial vaccines, Edmonston-Zagreb
(EZ, used in M-VACTM from Serum Institute of India) and Moraten
(used in Attenuvax® from Merck). Attenuvax and formulated
Moraten were thermally challenged at 40 ◦C for up to 8 h, and infec-
tion was quantiﬁed following Cellomics data acquisition using the
existing MVeGFP algorithm via an immunoﬂuorescence assay uti-
lizing a FITC-conjugated anti-measles antibody (Fig. 4c). Attenuvax
loses 1.0 log (90% counts) of activity after 8 h while formulations A
and C only experience a ∼0.6 log loss. The tricine-based formulation
H exhibited the greatest thermostability, losing only 0.35 log, simi-
lar to the results seen with MVeGFP. Interestingly, MVeGFP appears
to be less thermally stable than Moraten in the other common
formulations.
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Finally, the most promising formulations were combined with
Z vaccine strain virus, challenged at 40 ◦C for 4 h, and titered using
 plaque assay (Fig. 4d). Non-challenged, formulated virus was  used
s a control to calculate log loss and the plaque assay data again sup-
orts the HT screening data. The lead candidate formulations are
ighly stabilizing with no signiﬁcant loss in activity, whereas the
ommercial M-VACTM vaccine suffers >1 log loss. These infectivity
ata suggest that the two vaccine strains, Moraten and EZ, have
ifferential inherent thermal stability (e.g. formulation C in Fig. 4c
s. d) as has been suggested previously [37,38] which may  result
n slightly different behaviors in the same formulation. It is also
mportant to note that while vaccine-strain virus has been used to
alidate candidate formulations, manufacturing conditions for the
ommercial vaccines may  affect viral stability. For example, it has
een reported that the level of cytopathic effect during viral harvest
an affect the thermal stability of virus [37].
As proof of concept of broad transferability of the formulation
tability screening platform to non-related viruses, the screening
rocess was applied to adenovirus expressing eGFP (Ad-eGFP). A
inear response to increasing viral titer was seen with RSDs of
0–20% (Fig. 4e) showing that the assay has similar performance
haracteristics using either measles or adenovirus. However, Ad-
GFP is inherently more thermally stable than MVeGFP, losing all
nfectivity after 72 h at 37 ◦C (Fig. 4f) compared to just a few hours
t 37 ◦C for MVeGFP. The difference in thermal stability may  be
ttributed to the presence (measles) or absence (adenovirus) of a
iral envelope as the enveloped viruses are noted for greater tem-
erature sensitivity than non-enveloped viruses [39].
.  Discussion
Maintenance of vaccine efﬁcacy in the absence of a cold chain
as the potential to extend immunity against deadly diseases into
he world’s poorest communities and thereby save tens of thou-
ands of lives each year. Although alternative approaches for MV
tabilization are being explored [26,40], the reformulation of exist-
ng LAVs is a promising approach towards eliminating the need for
efrigeration during their storage, distribution, and use while not
equiring major modiﬁcations to the existing manufacturing pro-
ess. This screening platform allows for reformulation of existing
accines and could also be integrated into the formulation design
rocess in the developmental stage of new vaccines. Although in the
resent work, the screening process was applied towards increas-
ng LAV resistance to higher temperatures, an analogous process
ould be applied for addressing sensitivity to cold or freezing,
r towards optimization against performance metrics other than
nfectivity.
As a proof-of-concept, we applied the screening platform to MV,
nd several formulations were validated with vaccine strain virus
hat suffer <1.0 log loss after 8 h at 40 ◦C in the liquid state. This is a
igniﬁcant gain in thermal stability relative to two representative
ommercial vaccines (Attenuvax® and M-VACTM) and would allow
he reconstituted multi-dose vials of vaccine to be used for a full
orking day in a health clinic without access to refrigeration.
This  dataset represents the most comprehensive information
o date on the thermal stability of MV in liquid formulation, and
herefore may  be of broad interest to the MV  and vaccine devel-
pment communities. We  acknowledge that thermal stability in
he reconstituted (liquid) state must be paired with stability in
he lyophilized state. The HT screening platform described here
as been extended to address the more technically challenging
roblem of evaluating diverse lyophilized formulations, and we
ill report those results separately (High throughput screening of
yophilization conditions: application to the monovalent measles
accine; manuscript in preparation). Also, the underlying biophys-e 29 (2011) 5031– 5039
ical  effect of excipients on virus has not been explored during this
project; however, this topic is being rigorously pursued by other
groups [41].
In  order for a reformulation to be implemented, the change
must be attractive for the vaccine producer. We  recognize that
a ﬁrmly entrenched manufacturing process is a high barrier to
adoption. Furthermore, the levels of thermostability required for
refrigeration-free storage and distribution have not been a high
priority for pharmaceutical companies targeting developed world
markets where the cold chain is ubiquitous and reliable. However,
improved thermal stability promises a reduction in manufactur-
ing and distribution costs through elimination of vaccine wastage
and refrigeration infrastructure. Because many of the formulations
identiﬁed do not contain animal-derived products such as human
albumin or porcine gelatin, there are additional advantages in the
areas of cost of goods, regulatory concerns, and ethical/religious
considerations. As an alternative approach to complete reformu-
lation, a new diluent may  be used for reconstituting existing
lyophilized vaccines. For example, M-VACTM vaccine reconstituted
with a simple, inexpensive diluent (50 mM sodium citrate dihy-
drate pH 7.4) showed 0.5 log loss after 4 h at 40 ◦C (data not shown)
as compared to 2.5 log loss when reconstituted with water for injec-
tion.
5. Conclusion
The development of a robust, infectivity-based screening pro-
cess for identifying thermostable vaccine formulations offers
remarkable promise for vaccine development and reformulation of
both heat-sensitive (e.g. varicella, rotavirus, and OPV vaccines) and
cold-sensitive (H. inﬂuenzae type b, pneumococcal polysaccharide,
hepatitis vaccines) [42] vaccine products.
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